ArticleJournal for immunotherapy of cancer2021

Correction: Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.